Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Patients (PTS) with Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRALT): Phase 3 THOR Study

被引：0

作者：

Imkamp, Florian ^{[1
]}

Loriot, Yohann ^{[2
]}

Necchi, Andrea ^{[3
]}

Park, Se Hoon ^{[4
]}

Huddart, Robert ^{[5
]}

Burgess, Earle ^{[6
]}

Fu, Min ^{[7
]}

Santiago-Walker, Ademi ^{[7
]}

Mukhopadhyay, Sutapa ^{[7
]}

Naini, Vahid ^{[7
]}

Deprince, Kris ^{[8
]}

Monga, Manish ^{[7
]}

Siefker-Radtke, Arlene ^{[9
]}

机构：

[1] Hannover Univ, Dept Urol, Med Ctr, Hannover, Germany

[2] Inst Gustave Roussy, Villejuif, France

[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[4] Samsung Med Ctr, Seoul, South Korea

[5] Inst Canc Res, London, England

[6] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[7] Janssen Res & Dev, San Diego, CA USA

[8] Janssen Res & Dev, Beerse, Belgium

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

488

引用

页码：78 / 78

页数：1

共 36 条

[31] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
Galsky, Matt D.
Powles, Thomas
Li, Shengting
Hennicken, Delphine
Sonpavde, Guru
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC)
Siefker-Radtke, Arlene O.
Necchi, Andrea
Rosenbaum, Eli
Culine, Stephane
Burgess, Earle Frederick
O'Donnell, Peter H.
Tagawa, Scott T.
Zakharia, Yousef
OHagan, Anne
Avadhani, Anjali Narayan
Zhong, Bob
Santiago-Walker, Ademi E.
Roccia, Tito
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[33] Re: FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression Editorial Comment
Chang, Sam S.
JOURNAL OF UROLOGY, 2024, 211 (01): : 199 - 200
[34] Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
Hollebecque, A.
Borad, M.
Sahai, V.
Catenacci, D. V. T.
Murphy, A.
Vaccaro, G.
Paulson, A.
Oh, D-Y.
Feliz, L.
Lihou, C.
Zhen, H.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2018, 29 : 258 - 258
[35] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HRNMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.
Catto, James W. F.
Ben Tran
Master, Viraj A.
Roupret, Morgan
Pignot, Geraldine
Tubaro, Andrea
Shimizu, Nobuaki
Vasdev, Nikhil
Gschwend, Jurgen E.
Loriot, Yohann
Nishiyama, Hiroyuki
Redorta, Joan
Daneshmand, Siamak
Miura, Yuji
Naini, Vahid
Crow, Lauren
Triantos, Spyros
Baig, Mahadi
Steinberg, Gary D.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[36] Erst- oder Folgelinientherapie beim metastasierten oder nicht resektablen UrothelkarzinomOffene, einarmige, Phase 2, Multizenter-Studie zur Bewertung der Wirksamkeit und Verträglichkeit von INCB054828 bei Patienten mit metastasiertem oder nicht-resektablen Urothelkarzinom bei Vorliegen von FGF/FGFR-Alterationen (FIGHT-201) – AB 67/18 der AUOFirst- and further-line therapy in metastatic or unresectable urothelial carcinomaA phase 2, open-label, single-agent, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations (FIGHT-201) – AB 67/18 of AUO
H. Rexer
C.-H. Ohlmann
A. Stenzl
Forum, 2019, 34 (2) : 205 - 206

← 1 2 3 4 →